- Home
- CNSP
as 07-26-2024 4:00pm EST
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 2.5M | IPO Year: | 2019 |
| Target Price: | N/A | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -174.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $137.50 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CNS Pharmaceuticals Inc. (CNSP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Downs Christopher | CNSP | Chief Financial Officer | Feb 1 '24 | Buy | $0.30 | 66,666 | $19,999.80 | 103,438 | SEC Form 4 |
| Evans Carl Anthony | CNSP | Director | Feb 1 '24 | Buy | $0.30 | 33,333 | $9,999.90 | 33,458 | SEC Form 4 |
| Gumulka Jerzy | CNSP | Director | Feb 1 '24 | Buy | $0.30 | 33,333 | $9,999.90 | 43,006 | SEC Form 4 |
| Climaco John M | CNSP | Chief Executive Officer | Feb 1 '24 | Buy | $0.30 | 166,666 | $49,999.80 | 215,676 | SEC Form 4 |
Latest CNS Pharmaceuticals Inc. News
CNSP Breaking Stock News: Dive into CNSP Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a day ago
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
ACCESSWIRE
10 days ago
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
MT Newswires
12 days ago
CNS Pharmaceuticals Files Prospectus for Sale of Up to 2.4 Million Shares by Stockholders
MT Newswires
17 days ago
CNS Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule
MT Newswires
23 days ago
CNS Pharmaceuticals Prices Direct Offering; Shares Rise
ACCESSWIRE
23 days ago
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
MT Newswires
a month ago
Top Midday Decliners
ACCESSWIRE
a month ago
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
Compare CNSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNSP CNS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.